Enhancing Efficacy through CAR Structure Optimization: A Report by Leucid Bio.

 

In this webinar, Dr. Marc Davies, VP of R&D at Leucid Bio, outlines how the optimisation of CAR structure can be used to enhance T-cell efficacy. The move from a traditional ‘linear’ configuration, in which signalling domains are placed in cis (and thus progressively further from the plasma membrane) to a ‘lateral’ structure, in which the signalling domains are placed across the plasma membrane (and thus at their endogenous membrane-proximal locations) enhances the proliferation, survival and anti-tumour activity of the CAR T-cells, resulting in substantial efficacy across multiple in vivo models of solid tumours. These lateral CAR T-cells can then be combined with appropriate armouring technologies to further enhance anti-tumour efficacy.

Optimizing CAR structures to enhance efficacy

The content of this webinar is outstanding. Dr. Marc's delivery is coherent and user-friendly. The preliminary findings regarding the new adaptor CAR-T are notably promising, especially when compared to traditional CAR-T methods. Additionally, Leucid Bio's pioneering approach to CAR T-cell expansion using IL-4 is truly captivating.